Responding to the Centers for Medicare & Medicaid Services’ physician fee schedule proposed rule for calendar year 2021, the AHA said it appreciates the agency’s effort to continue certain pandemic-era policies that have helped hospitals and health systems ensure access to care for patients during the COVID-19 public health emergency.

“In particular, we support CMS’s proposal that would allow physicians and non-physician practitioners to continue providing direct supervision via interactive telecommunications technology; we urge the agency to make permanent this policy,” AHA said. “We also appreciate CMS’s proposals to permanently retain some of the telehealth services it added to the Medicare telehealth list of services during the PHE and temporarily retain other services it added during the PHE. The AHA also supports CMS’ proposal to delay until CY 2022 at the earliest implementation of the Merit-based Incentive Program’s Value Pathways approach.”

In addition, AHA also expressed concern about other proposed policies, particularly those made more problematic by the ongoing COVID-19 pandemic. “The proposed significant reduction to the Medicare conversion factor that is a result of CMS’ proposal to implement the evaluation & management (E/M) revaluation and other changes in a budget-neutral manner would significantly strain the finances of hospitals and health systems,” AHA said.  

Among other comments, AHA expressed concern regarding the proposal to create a new MIPS Advanced Payment Pathway that asks all MIPS alternative payment models to report the same six quality measures, as well as concerns about proposed changes to the Medicare Shared Savings Program quality measurement approach.

Read the full letter for AHA’s detailed comments on the rule.

Related News Articles

Headline
The AHA Jan. 31 commended Sens. Bill Cassidy, R-La., Catherine Cortez Masto, D-Nev., John Cornyn, R-Texas., and Michael Bennet, D-Colo., on draft legislation…
Headline
The White House Feb. 1 announced it placed tariffs on imported goods from Canada, Mexico and China. The tariffs for Mexico and Canada have since been delayed…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
The White House Office of Management and Budget Jan. 29 rescinded a memo it issued two days earlier directing federal agencies to temporarily pause federal…
Headline
The AHA Jan. 28 voiced support for bipartisan legislation to reauthorize for five years the Dr. Lorna Breen Health Care Provider Protection Act, which provides…
Headline
The White House Office of Management and Budget late Jan. 27 issued a memo directing federal agencies to temporarily pause federal grants, loans and other…